---
figid: PMC9549728__EMMM-14-e15705-g003
pmcid: PMC9549728
image_filename: EMMM-14-e15705-g003.jpg
figure_link: /pmc/articles/PMC9549728/figure/emmm202215705-fig-0003ev/
number: Figure EV3
figure_title: Dose–response curves of normal and organoid models upon treatment with
  classical chemotherapeutics and targeted therapies
caption: A–EDrug response curves upon treatment with (A) classical chemotherapeutics
  (cisplatin, epirubicin, doxorubicin, docetaxel, paclitaxel, bleomycin, and mitomycin
  C), (B) HDAC inhibitors (belinostat, tacedenaline, and vorinostat), (C) PI3K/mTOR
  inhibitors (copanlisib, PF‐04691502, and everolimus), (D) EGFR inhibitors (osimertinib,
  erlotinib, canertinib, lapatinib, and neratinib) and (E) MEK1/2 inhibitors (cobimetinib
  and trametinib) (biological replicates n = 3, data are shown as mean ± SD).
article_title: Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway
  activation in gastric cancer.
citation: Therese Seidlitz, et al. EMBO Mol Med. 2022 Oct;14(10):e15705.
year: '2022'

doi: 10.15252/emmm.202215705
journal_title: EMBO Molecular Medicine
journal_nlm_ta: EMBO Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- gastric cancer
- HDACi
- MAPK
- organoids
- Cancer
- Signal Transduction

---
